Proactive Investors - Run By Investors For Investors

Emerald Health Therapeutics completes setting up of Emerald Health Naturals joint venture

The new venture will distribute products to treat stress, anxiety, restless sleep, and other conditions using non-cannabis ingredients to Canadian natural health product stores and pharmacies
Two business executivces shaking hands
Emerald Health Therapeutics has invested C$5 million for a 51% equity stake in the joint venture, known as Emerald Health Naturals

Vancouver-based cannabis company Emerald Health Therapeutics Inc’s (CVE:EMH) (OTCQX:EMHTF) announced Thursday that it has completed the setting up of Emerald Health Naturals, its 51:49 joint venture with San Diego-based Emerald Health Bioceuticals.

Emerald Health Therapeutics has invested C$5 million for a 51% equity ownership of Emerald Health Naturals while Emerald Health Bioceuticals granted exclusive Canadian distribution rights to its product line in exchange for a 49% equity stake in the joint venture.

READ: Emerald Health Therapeutics receives Health Canada licenses for its natural products line

Emerald Health Bioceutical’s product line consists of nutritional supplements that use non-cannabis, non-psychoactive plant-based bioactive compounds to support the body’s endocannabinoid system.

The products, including Endo Sleep, Endo Inflame, Endo Brain, Endo Bliss and Endo Calm, were designed to treat stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

“We have the unique opportunity to brand Emerald through Emerald Health Naturals offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” Executive Chairman Avtar Dhillon told Proactive Investors.

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

Emerald also recently strengthened its intellectual property portfolio via a partnership with the cannabis-focused research facility VivaCell Biotechnologies. The institute will work with Emerald Health to evaluate formulas and determine consistent dosages as the company continues to develop medical and recreational cannabis products.

 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full EMH profile View Profile

Emerald Health Therapeutics Inc Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 16 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme
car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use